AIRLINK 71.20 Increased By ▲ 2.00 (2.89%)
BOP 5.04 Increased By ▲ 0.14 (2.86%)
CNERGY 4.36 Increased By ▲ 0.10 (2.35%)
DFML 31.95 Increased By ▲ 0.70 (2.24%)
DGKC 80.50 Increased By ▲ 3.25 (4.21%)
FCCL 21.15 Increased By ▲ 1.15 (5.75%)
FFBL 35.20 Increased By ▲ 0.20 (0.57%)
FFL 9.31 Increased By ▲ 0.19 (2.08%)
GGL 9.79 Decreased By ▼ -0.01 (-0.1%)
HBL 112.30 Decreased By ▼ -0.46 (-0.41%)
HUBC 135.43 Increased By ▲ 2.39 (1.8%)
HUMNL 7.05 Increased By ▲ 0.10 (1.44%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.39 Increased By ▲ 0.14 (3.29%)
MLCF 37.55 Increased By ▲ 0.95 (2.6%)
OGDC 136.60 Increased By ▲ 3.73 (2.81%)
PAEL 23.63 Increased By ▲ 0.99 (4.37%)
PIAA 24.49 Increased By ▲ 0.29 (1.2%)
PIBTL 6.61 Increased By ▲ 0.15 (2.32%)
PPL 121.50 Increased By ▲ 5.20 (4.47%)
PRL 27.08 Increased By ▲ 1.18 (4.56%)
PTC 13.30 Increased By ▲ 0.22 (1.68%)
SEARL 52.40 Increased By ▲ 0.40 (0.77%)
SNGP 70.37 Increased By ▲ 2.77 (4.1%)
SSGC 10.55 Increased By ▲ 0.01 (0.09%)
TELE 8.40 Increased By ▲ 0.12 (1.45%)
TPLP 11.05 Increased By ▲ 0.25 (2.31%)
TRG 60.00 Increased By ▲ 0.71 (1.2%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,518 Increased By 109.2 (1.47%)
BR30 24,601 Increased By 564.5 (2.35%)
KSE100 71,736 Increased By 1068.7 (1.51%)
KSE30 23,517 Increased By 293 (1.26%)

WASHINGTON: The US Centers for Disease Control and Prevention (CDC) on Thursday recommended Covid-19 booster shots from Pfizer and Moderna targeting the Omicron variant, clearing the way for the administration of the shots.

This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States.

The Pfizer-BioNTech shot is recommended for people 12 and older and Moderna’s for those 18 years and up.

“The updated Covid-19 boosters are formulated to better protect against the most recently circulating Covid-19 variant. They can help restore protection that has waned since previous vaccination and were designed to provide broader protection against newer variants,” CDC Director Rochelle Walensky said in a statement.

“This recommendation followed a comprehensive scientific evaluation and robust scientific discussion,” she added.

COVID drives down US life expectancy for the second straight year

The new versions of the vaccines – which were approved by the US Food and Drug Administration on Wednesday – could potentially be available in the United States as early as next week.

The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.

In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.

Comments

Comments are closed.